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Abstract
Epidermal growth factor receptor (EGFR) kinase domain mutations hyperactivate the kinase and confer kinase addiction 
of the non-small-cell lung cancer (NSCLC) tumor cells. Almost all of these mutations are located within exons 18-21. 
The -216 single nucleotide polymorphism in the promoter region is associated with increased EGFR production. We 
present a method for detecting these common mutations in 81 cases of NSCLC. The protocol is based on the multiplex 
amplification of promoter region and exons 18-21 of the EGFR genes in a single tube, followed by primer extension of 
the PCR products using various sizes of primers to detect base changes at -216 promoter region and codons 719, 746-
750, 790, 858 of the EGFR gene. We compared the results with that from direct sequencing for detecting EGFR 
mutations in 81 cases of NSCLC. The two methods identified the same 26 mutations, but our method is superior to 
direct sequencing in terms of the amount of work and time required. We presented a simple and fast method to detect 
mutations of EGFR genes in NSCLC.
Background
Lung cancer is one of the most common cancers in the
world and is responsible for one third of all cancer-related
death. Treatment of lung cancer mainly depends on the
type of the cells that make up the cancer. Small-cell lung
cancer (SCLC) which comprises about 20% of lung can-
cers originates from neuroendocrine cells in the bron-
chus. SCLC responds well to chemotherapy initially, but
resistance occurs commonly. Non-small-cell lung cancer
(NSCLC), comprising 80% of lung cancers, arises from
lung epithelial cells, and comprises diverse histological
subtypes that includes adenocarcinoma, bronchioloalve-
olar, squamous, anaplastic and large-cell carcinomas [1].
NSCLC is often treated with combination cytotoxic che-
motherapy, but the treatment only results in a modest
increase in survival. The receptor tyrosine kinases (RTKs)
serve as cell signalling mediators by receptor-specific
ligands. Epidermal growth factor receptor (EGFR) is a
member of the ErbB family of RTKs expressed in many
cases of NSCLC, and its expression is correlated with a
poor prognosis [2-5]. Two EGFR small molecule inhibi-
tors, gefitinib and erlotinib, which target the tyrosine
kinase domain of EGFR have been approved for the treat-
ment of advanced NSCLC. Females, Asians, nonsmokers,
and those with bronchioloalveolar carcinoma appear to
derive the most benefit from gefitinib or erlotinib [6-10].
Molecular analysis showed that the majority of respond-
ers harbored specific mutations in the gene that encodes
EGFR [8,10-12]. EGFR kinase domain mutations occur
primarily in exons 18-21 which encode part of the
tyrosine kinase (TK) domain [13-15]. Besides these EGFR
kinase domain mutations, a common single nucleotide
polymorphisms (SNP) located -216 bp upstream from the
initiator ATG in the promoter region also has been iden-
tified. The SNP occurs at an important binding site for
the transcription factor SP1 that is necessary for activa-
tion of EGFR  promoter activity and correlates with
increased promoter activity and expression of EGFR
mRNA [16].
In this study, we performed multiplex amplification of
exons 18-21 and promoter of EGFR  using five pair of
primers followed by primer extension to detect base
changes or deletions in codons 719, 746-750, 790, 858,
and -216 promoter to analyze the mutational frequency
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in 81 cases of lung cancer, and compared the results to
that obtained by direct sequencing.
Methods
Tissue Procurement
Tumor specimens, obtained from patients on protocols
approved by the Institutional Review Board of Changhua
Christian Hospital, were collected from eighty-one
p a t i e n ts  wi t h  NSCL C  a t  t h e  t i m e  o f  s u r gi ca l  r e sect i o n
before systemic treatment. All specimens were frozen
immediately and stored in liquid nitrogen until DNA was
extracted.
DNA extraction, PCR and direct sequencing of the EGFR 
gene
DNA extraction was performed as previously described
[17]. Five separate PCR reactions, each with the corre-
sponding pair of primers, were used to amplify the pro-
moter region and exons 18-21 of the EGFR genes (Table
1). PCR amplification of 0.2 μg DNA was performed with
a denaturing step at 94°C for 5 min, then 30 sec at 94°C, 1
min at 58°C, and 1 min at 72°C for 35 cycles, followed by a
final 5 min at 72°C. The PCR products were visualized on
a 2.5% agarose gel. These PCR products were then sub-
jected to direct sequencing using the same primers, and
all mutations were confirmed by sequences originating
from both the upstream and downstream primers. Direct
sequencing was performed on a Beckman Coulter CEQ
8000 Series Genetic Analysis System (Beckman Coulter
Inc., Fullerton, CA, USA) according to manufacturer
instructions.
Multiplex PCR and primer extension analysis of mutations 
in EGFR-216 promoter region and exons 18, 19, 20, and 21
Multiplex PCR was used to amplify the promoter region
and exons 18-21 of the EGFR genes in a single tube. The
primers and conditions used for the multiplex PCR were
the same as the PCR described above. After multiplex
PCR amplification, the PCR products were purified to
remove the remaining primers and unincorporated
deoxynucleotide triphosphates, using the PCR-M™ Clean
Up System (Viogene-biotek Co., Sunnyvale, CA, USA).
After removing the primers, the products were subjected
to primer extension analysis. Various concentrations of
probe for -216 promoter region and exons 18-21 were
added to the tube containing 1.5 μl of purified PCR prod-
ucts (T able 2), as well as 4 μl of ABI PRISM SNaPshot
Multiplex Kit (Applied Biosystems, Foster City, CA) con-
taining AmpliTaq®  DNA polymerase and fluorescently
labeled dideoxynucleotide triphosphates (ddNTPs)
(RGG-labeled dideoxyadenosine triphosphate, TAMRA-
labeled dideoxycytidine triphosphate, ROX-labeled dide-
oxythymidine triphosphate, and R110-labeled dideox-
yguanosine triphosphate). Each 10-μl mixture was
subjected to 25 single-base extension cycles consisting of
a denaturing step at 96°C for 10 sec, and primer annealing
and extension at 60°C for 35 sec. After cycle extension,
unincorporated fluorescent ddNTPs were incubated with
1 μl of shrimp alkaline phosphatase (SAP) (United States
Biochemical Co., Cleveland, USA), at 37°C for 1 hour, fol-
lowed by enzyme deactivation at 75°C for 15 min.
The primer extension reaction products were resolved
by automated capillary electrophoresis on a capillary
electrophoresis platform. Briefly, 14 μl of Hi-Di™ Forma-
mide (Applied Biosystems) and 0.28 μl of GeneScan™ -
120LIZ® Size Standard (Applied Biosystems) were added
to 6 μl of primer extension products. All samples were
loaded and run on an ABI Prism 310 DNA Genetic Ana-
lyzer (Applied Biosystems) following the manufacturer's
recommendations. Following the run, samples were ana-
lyzed using GeneScan™ 3.1 application software (Applied
Biosystems).
Results
Patients
We used multiplex PCR plus primer extension method to
detect EGFR -216 promoter region and exons 18-21
mutations in 81 cases of NSCLC (Figure 1). Histologi-
cally, there were 26 adenocarcinomas, 6 bronchioloaveo-
lar carcinomas, 33 squamous cell carcinomas, 5
adenosquamous carcinomas, and 11 other types of
NSCLCs.
Multiplex PCR and primer extension
For mutation analysis of codons 719 in exon 18, we used
different-sized primers to recognize the change of the
first and second base separately. In-frame deletion
between codon 746 and 752 in codon 19 was analyzed
with primers made to be different in size either by adding
different lengths of poly(dT) tails to the 5'-end or extend-
ing the primer sequence to allow separation based on the
Table 1: PCR Primers used to amplify promoter region and 
exons 18, 19, 20, and 21 of the EGFR genes
EGFR gene Sequence
E18-5' 5'-CTGGCACTGCTTTCCAGCAT-3'
E18-3' 5'-GCTTGCAAGGACTCTGGGCT-3'
E19-5' 5'-GCATCGCTGGTAACATCCAC-3'
E19-3' 5'-AGATGAGCAGGGTCTAGAGC-3'
E20-5' 5'-ATCGCATTCATGCGTCTTCA-3'
E20-3' 5'-AGACCGCATGTGAGGATCCT-3'
E21-5' 5'-TGACCCTGAATTCGGATGCA-3'
E21-3' 5'-ATACAGCTAGTGGGAAGGCA-3'
Promoter 5' 5'-CCTCCTCTGCTCCTCCCGAT-3'
Promoter 3' 5'-CGGGGCTAGCTCGGGACT-3'Lin et al. Journal of Biomedical Science 2010, 17:37
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differences in size. SNP at -216 promoter region and mis-
sense mutations which result in L858R change in exon 21
and T790M in exon 20 were each analyzed with a single
probe.
The overall mutation (in EGFR TK domain and -216
promoter) rate was 32% (26 of 81).
Mutations in exons 18-21 of EGFR TK domain were
detected in 19 (23%) of the 81 NSCLCs in which there
were 12 adenocarcinomas, three bronchioloaveolar carci-
nomas, two squamous cell carcinomas, one ade-
nosquamous carcinoma, and one other type of NSCLC.
No mutation was detected at codon 719 in exon 18 and
codon 790 in codon 20. Seven tumors had in-frame dele-
tions within exon 19, resulting in the loss of codons 746
through 750 in six tumors, and loss of codon 747 through
752 in one tumor. 12 cases had a 2573 T>G mutation
resulted in L858R change. SNP -216 in the promoter
region were detected in seven (8.6%) cases that include
three adenocarcinomas, one bronchioloaveolar carci-
noma, three squamous cell carcinomas. Three patients
with SNP -216 in the promoter region had another muta-
tion in exon 21 (L858R). Results of the multiplex PCR and
primer extension mutation analysis of the EGFR gene are
listed in Table 3.
Direct Sequencing
We also used direct sequencing to analyze the -216 pro-
moter region and exons 18-21 of the EGFR gene. The
results of sequencing analysis were identical to the results
of multiplex PCR with primer extension analysis. No
other mutation was identified by direct sequencing. We
can therefore conclude that our method was very accu-
rate in profiling the most common EGFR mutations in
NSCLC.
Discussion
EGFR proteins control essential signaling pathways that
regulate cell proliferation [18]. Increased levels of EGFR
gene expression are observed in many cancers, including
NSCLC, and its expression is correlated with an adverse
prognosis [2-4,19]. Clinical responsiveness to gefitinib
and erlotinib in NSCLC have been shown to correlate
with somatic mutations in the EGFR gene, which result in
increased sensitivity to inhibition of growth by the drugs
[8,10-12]. EGFR mutations have been found more fre-
quently in non-smoking East Asian women with adeno-
carcinoma with bronchioalvelar features [14,20-26].
A protocol based on mutant-enriched PCR followed by
primer extension of the PCR products was used to detect
EGFR  T790M mutation in NSCLC [27]. We recently
demonstrated a simple and fast way to identify K-RAS
mutation [17]. In this study, we extend the application to
detect -216 promoter region and exons 18-21 mutations
of EGFR gene simultaneously and apply this method to
investigate the mutation status in 81 cases of NSCLC. We
compared the results with that from direct sequencing
Table 2: Primer extension mutation analysis probes for -216 promoter region and codons 719, 746-750, 790, and 858 of 
the EGFR genes
Nucleotide number and 
sequence
Amino acid change Sequence Size
2155 G>T, 2155 G>A G719C, G719S 5'-TGAATTCAAAAAGATCAAAGTGCTG-3' 25 mer
2156 G>C G719A 5'-AAACTGAATTCAAAAAGATCAAAGTGCTGG-3' 30 mer
2235-2249 del E746-A750 del 5'-GAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAA-3' 35 mer
2236-2250 del E746-A750 del 5'-TCCCAGAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAAG-3' 41 mer
2237-2254 del E746-T751 del 5'-(T)20AGTTAAAATTCCCGTCGCTATCAAGG-3' 46 mer
2240-2257 del L747-S752 del 5'-(T)23AGTTAAAATTCCCGTCGCTATCAAGGAAT-3 52 mer
2573 T>G L858R 5'-(T)26ACCGCAGCATGTCAAGATCACAGATTTTGGGC-3' 58 mer
2369 C>T T790M 5'-CTCCACCGTGCAGCTCATCA-3' 20 mer
-216 G/T 5'-GGCCGCAGCAGCCTCC-3' 16 merLin et al. Journal of Biomedical Science 2010, 17:37
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for detecting EGFR mutations in 81 cases of NSCLC. The
two protocols identified the same 26 mutations, but the
new method is superior to direct sequencing in terms of
the amount of work and time required. With this method,
-216 promoter region and exons 18-21 of the EGFR gene
were amplified with multiplex PCR in a single tube and
the detection of mutations in the EGFR promoter and
four key exons can be combined into one assay. This
allows a sample to be screened for all common EGFR
mutations simultaneously. We previously reported that
Figure 1 Detection of wild-type and mutant EGFR by primer extension analysis. NSCLC DNA samples of wild-type EGFR and ones containing the 
following mutations: -216 G/T, 2235-2249 del, 2236-2250 del, 2240-2257 del, and 2573 T>G.Lin et al. Journal of Biomedical Science 2010, 17:37
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that as little as 10 ng of DNA was enough for the multi-
plex PCR reaction and we also showed that this method
can detect mutations against a background of up to at
least 23 wild-type alleles [3]. Moreover, because the tech-
nique is a sequencing-based approach, additional
sequencing is not necessary.
Distinguishing sequence variants with primer exten-
sion is based on the high accuracy of nucleotide incorpo-
ration catalyzed by a DNA polymerase. Current products
of the thermostable enzymes used in primer extension
have very low error rates and are specific for ddNTPs
[28]. These characteristics provide negligible primer mis-
incorporation and excellent discrimination between wild,
heterozygous and homozygous genotypes. Another
advantage of the primer extension reaction is its multi-
plexing capability, with several mutations being detected
in a single reaction tube. Multiplex PCR-SSCP- or PCR-
ARMS-based methods can also simultaneously detect
several mutations. However, PCR-SSCP require further
confirmation by direct sequencing, and PCR-ARMS
require more primers than are possible in a single reac-
tion to detect all mutations at -216 promoter region and
exons 18-21 of the EGFR gene. The primer extension
reaction is a less time-consuming assay because auto-
mated fluorescent capillary electrophoresis of the prod-
ucts requires only 25 minutes in comparison with
capillary electrophoresis required for standard sequenc-
ing that takes more than an hour.
Conclusions
The method that we demonstrated in this report provides
a rapid way to identify common EGFR mutations for the
purpose of clinical evaluation in NSCLC. The method
can also be applied in the detection of other mutations in
the EGFR gene.
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